drugset
Drugs / Resimmune®
last change May 2026 re-read 9 days ago

Resimmune®

also known as A-dmDT390-bisFv(UCHT1) · LAX-699

Protein / enzyme biologic targets CD3E, EEF2 via inhibition

Developed for
melanoma · mycosis fungoides · Sezary syndrome · T-cell leukemia
Investigated by
Virogen Biotechnology Inc. · James Graham Brown Cancer Center · Scott and White Hospital & Clinic · University of Texas Southwestern Medical Center · Yale University · City of Hope National Medical Center
+15 more · Columbia University · Dana-Farber Cancer Institute · H. Lee Moffitt Cancer Center and Research Institute · M.D. Anderson Cancer Center · Northwestern University · Ohio State University Comprehensive Cancer Center · Rush University Medical Center · Stanford University · Thomas Jefferson University · University of Arkansas · University of Colorado, Denver · University of Louisville · University of Washington · Vanderbilt University School of Medicine · Washington University School of Medicine

Trials 4

today NCT02943642 · Ph 2 NCT02990416 · Ph 1/2 NCT01888081 · Ph 1/2 NCT00611208 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT02990416 Jan 2017 → Feb 2018 melanoma Virogen Biotechnology Inc. Unknown No outcome recorded
Phase 1/2 NCT01888081 Feb 2014 → Dec 2020 melanoma Virogen Biotechnology Inc. Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT02943642 May 2026 mycosis fungoides Virogen Biotechnology Inc. Withdrawn No outcome recorded
Phase 2 NCT00611208 Jan 2008 → Feb 2015 Sezary syndrome, T-cell leukemia, mycosis fungoides Virogen Biotechnology Inc. Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Resimmune “A-dmDT390-bisFv(UCHT1) (Resimmune®)” NCT01888081 ↗
Known as A-dmDT390-bisFv(UCHT1) ClinicalTrials.gov intervention name — accepted as the source's own label NCT02943642 ↗
3

NCT00611208 ↗

NCT01888081 ↗

NCT02990416 ↗
Known as LAX-699 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297555 ↗
Action Deplete “degree of T cell depletion induced by A-dmDT390-bisFv(UCHT1) fusion protein” NCT00611208 ↗
Action Inhibit “Elongation factor 2 inhibitor” CHEMBL4297555 ↗
Modality Protein / enzyme biologic “A-dmDT390-bisFv(UCHT1) (Resimmune™), an anti-T cell immunotoxin” NCT01888081 ↗
Route Intravenous “into a free flowing IV” NCT00611208 ↗
Target CD3E “T-cell surface glycoprotein CD3 epsilon chain binding agent” CHEMBL4297555 ↗
Target EEF2 “Elongation factor 2 inhibitor” CHEMBL4297555 ↗